Achillion Pharmaceuticals

Achison, Inc. engages in providing online advertising services. The firm offers services with the focus on website development, maintenance, and promotion. The company was founded on December 29, 2014 and is headquartered in Flushing, NY.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Antiaging Quantum Living, Inc. engages in the provision of online advertising services. The firm offers services with a focus on website development, maintenance, and promotion. The company was founded on December 29, 2014 and is headquartered in Flushing, NY.

BLUE BELL, Pa., Dec.  19, 2019  (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that its shareholders have approved the acquisition of Achillion by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN). Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020.

Achillion Shareholders Approve Agreement to be Acquired by Alexion

– 2.4 g/dL mean increase in hemoglobin at 24 weeks –   – Reduction in blood transfusions from 34 to 1; and improvements in markers of hemolysis –-   Completed End of Phase 2 Meeting; Phase 3 Trial Initiation in early 2020 -

Achillion Reports Positive Data from Phase 2 Study of Danicopan (ACH-4471) in Combination with Eculizumab in PNH Patients who Have an Inadequate Response to Eculizumab Monotherapy at the 61st American Society of Hematology Meeting

Achillion (ACHN) reported earnings 30 days ago. What's next for the stock?

Why Is Achillion (ACHN) Down 2.8% Since Last Earnings Report?

Digital Turbine

ConforMIS

EverBank Financial

iShares Russell 2000 ETF

Kodiak Sciences Inc

Inside the best performing stocks of the Russell 2000 ETF.

5 Stocks That Pushed Russell 2000 ETF Higher

Achillion's (ACHN) lead pipeline candidate danicopan receives PRIME status from the EMA as a treatment option for PNH in patients, who are not adequately responding to a C5 inhibitor.

Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH

– Phase 3 PNH initiation planned early 2020 – – Phase 3 PNH initiation planned early 2020 –

European Medicines Agency Grants PRIME Designation to Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients Who Are Not Adequately Responding to a C5 Inhibitor

BLUE BELL, Pa., Nov.  11, 2019  (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug Application (IND) for ACH-5228, the Company’s second-generation oral factor D inhibitor. The opening IND study in the United States will be a drug-drug interaction study with ACH-5228. The Company expects to begin a Phase 2 proof-of-concept paroxysmal nocturnal hemoglobinuria (PNH) clinical trial of ACH-5228 in the first half of 2020.  

Achillion Announces Clearance of Investigational New Drug Application for ACH-5228

First Majestic Silver

Tech Data

Buyout talk played a big role in several stocks' moves.

Why Achillion Pharmaceuticals, Tech Data, and First Majestic Silver Jumped Today

Alexion Pharmaceuticals will reportedly buy clinical-stage rival Achillion Pharmaceuticals in an all-cash deal.

Why Achillion Pharmaceuticals Stock Is Skyrocketing Today

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) shares skyrocketed on Wednesday morning after an announcement that the firm would be acquired by Alexion Pharmaceuticals Inc.

Are Shareholders Getting Enough in the Achillion Acquisition?

Alexion Pharma

Alexion Pharma (NASDAQ: ALXN) will buy Achillion Pharma (NASDAQ: ACHN) for the initial value of $930 million, or $6.30 per share in cash plus added contingent considerations for total potential value of $8.30 per share.

Alexion To Acquire Achillion Pharma For $930M

Shares of Achillion Pharmaceuticals Inc. ACHN, +2.82% rocketed 82% in premarket trading Wednesday, after the biopharmaceutical company agreed to be acquired by Alexion Pharmaceuticals Inc.

Achillion Pharmaceuticals' stock rockets after Alexion Pharmaceuticals $930 million buyout deal

Achillion Pharmaceuticals receives Breakthrough Therapy Designation for danicopan in combination with a C5 inhibitor for the treatment of patients with paroxysmal nocturnal hemoglobinuria.

Achillion Makes Significant Advancement With FDA Designation, Sets Up Big Catalysts In Coming Months

Achillion recently reported Phase 1 results of ACH-5228 which seems to have addressed the limitations of danicopan.

Achillion Pharmaceuticals: ACH-5228 De-Risking Gets Noticed

Achillion's (ACHN) oral factor D inhibitor, danicopan, receives Breakthrough Therapy designation from the FDA as a treatment option for PNH. Shares up.

Achillion's Danicopan Gets Breakthrough Therapy Tag for PHN

BLUE BELL, Pa., Sept.  26, 2019  (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President and Chief Executive Officer of Achillion will present at the 2019 Cantor Fitzgerald Global Healthcare Conference on Thursday, October 3, 2019, at 8:55 a.m. ET at the InterContinental New York Barclay in New York, NY.

Achillion to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

Investors are responding enthusiastically to a key FDA designation for the biotech's leading pipeline candidate.

Why Achillion Pharmaceuticals Stock Is Jumping Today

Achillion Pharmaceuticals Inc. (NASDAQ: ACHN) has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for danicopan (ACH-4471) in combination with a C5 monoclonal antibody for patients with paroxysmal nocturnal hemoglobinuria (PNH) who are suboptimal responders to a C5 inhibitor alone.

Achillion Pharma Wins Big With FDA Breakthrough

– Danicopan Phase 2 PNH combination therapy topline data expected Q4 2019 –  – Initiation of Phase 3 planned for early 2020 –

Achillion Receives Breakthrough Therapy Designation from FDA for Danicopan for Treatment of Paroxysmal Nocturnal Hemoglobinuria

Why Is Achillion (ACHN) Down 11.2% Since Last Earnings Report?

BLUE BELL, Pa., Aug.  29, 2019  (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement-mediated diseases, today announced that Joseph Truitt, President and Chief Executive Officer of Achillion will present at the Baird 2019 Global Healthcare Conference on Thursday, September 5, 2019, at 12:50 p.m. ET at the InterContinental New York Barclay in New York, NY.

Achillion to Present at the Baird 2019 Global Healthcare Conference

With little sell side coverage, there is no investor awareness of the potential of its compounds ACH-4471 and ACH-5228 in the complement space.

Achillion Has Multiple Shots On Goal In The Complement Space

Achillion Pharmaceuticals delivered extremely robust outcomes for the Phase 1 study of ACH-5228 and thereby galvanized the shares to trade multiple folds higher.

Achillion: Shifted Gears For Success

Achillion (ACHN) meets bottom-line estimates in the second quarter. The absence of an approved product results in no revenues in the quarter.

Achillion (ACHN) Reports Wider Y/Y Loss in Q2, Revenues Nil

Achillion Pharmaceuticals reports positive data from a phase 1 study using ACH-5228 as a treatment for complement mediated diseases.

News for Achillion Pharmaceuticals Stock (ACHN)